News Releases

Date Title and Summary
Toggle Summary Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results
– Nine product candidates in clinical trials against eight different targets – – Pivotal trial for JCAR017 in r/r DLBCL expected to start in 2017 – – Phase I JCAR017 demonstrates 80% overall response and 60% complete response in r/r DLBCL – – Discontinuing development of JCAR015 in r/r adult ALL to
Toggle Summary Juno Therapeutics to Present at March 2017 Investor Conferences
SEATTLE --(BUSINESS WIRE)--Feb. 28, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. Hans Bishop , Juno’s President and Chief Executive Officer,
Toggle Summary Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1
SEATTLE --(BUSINESS WIRE)--Feb. 22, 2017-- Juno Therapeutics, Inc. (NASDAQ:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2016 , on Wednesday, March 1, 2017 , after the close of U.S.-based financial markets. Following the announcement, Juno management will
Toggle Summary Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations
Experienced executive brings demonstrated operational excellence to Juno, will lead newly formed group focused on development operations SEATTLE --(BUSINESS WIRE)--Jan. 27, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for
Toggle Summary Juno Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
SEATTLE --(BUSINESS WIRE)--Jan. 3, 2017-- Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced that it will webcast its presentation at the 35 th Annual J.P. Morgan Healthcare Conference at 4:30 p.m. PT on Tuesday, January 10, 2017 . The presentation will feature a business overview and update by
Toggle Summary Juno Therapeutics’ and Celgene Corporation’s Investigational Drug JCAR017 Granted Breakthrough Therapy Designation from FDA and Priority Medicines Eligibility from EMA for Relapsed/Refractory Diffuse Large B-cell Lymphoma
-- Early results recently announced with JCAR017 in non-Hodgkin lymphoma and pediatric acute lymphoblastic leukemia -- Pivotal DLBCL trial expected to begin in 2017 SEATTLE & SUMMIT, N.J. --(BUSINESS WIRE)--Dec. 20, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDAQ:
Toggle Summary Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell Patent
SEATTLE --(BUSINESS WIRE)--Dec. 19, 2016-- Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it has defeated an attempt to invalidate a patent exclusively licensed by Juno that covers,
Toggle Summary Juno Therapeutics Highlights Progress with Best-in-Class Strategy in B-Cell Malignancies at ASH
-- Studies of JCAR017 in pediatric ALL patients shows 93% CR, and new data on adverse event management -- 88% of patients with CD19-negative ALL achieved CR at dose level 2 of CD22-targeted JCAR018 -- TRANSCEND study of JCAR017 in NHL shows 80% overall response and 60% complete response, with no
Toggle Summary Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma
-- 80% overall response and 60% complete response -- No severe cytokine release syndrome to date and 14% rate of severe neurotoxicity -- Side effect profile plus cell persistence suggest potential for combination therapy SEATTLE --(BUSINESS WIRE)--Dec. 5, 2016-- Juno Therapeutics, Inc.
Toggle Summary Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL
-- 88% complete marrow response by flow cytometry in efficacy-evaluable patients --100% progression-free and overall survival in patients with undetectable disease in bone marrow -- Study data support the development of JCAR017 in CLL SEATTLE --(BUSINESS WIRE)--Dec.